16 May 2018 - - San Francisco, California-based market research and consulting firm Radiant Insights, Inc. predicts the global Huntington's disease therapeutics market will grow at a steady CAGR in the future, the company said.
Hungtington's disease, mainly prevalent in adults, is a chronic and progressively neurodegenerative disease that is characterised by characterized radiologically by striatal atrophy of varying degree. It causes choreic involuntary movements followed by psychiatric, psychological, and intellectual disorders.
Commercial market driving factors responsible for the growth of Hungtington's disease therapeutics include unmet medical needs, a rise in pharmaceuticals, and the inception of innovative drugs. However, stringent regulations by government coupled with minimal approval for drugs hampers the market growth in the estimated period.
Geographically, the Huntington's disease therapeutics market spans North America, Latin America, Europe, Middle-East, Asia-Pacific and Africa.
North America dominated the global market owing to rising cases of the disease and therapy for the same. Europe and MEA regions however witnessed a steady CAGR growth. APAC regions also exhibited a steady CAGR growth rate in the estimated period owing to rising cases of Huntington's disease.
Radiant Insights aims to reach the highest levels of customer satisfaction. Its representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.